Syngenta AG
http://www4.syngenta.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Syngenta AG
In Brief
Naturex acquires Decas to enter UTI ingredient market; TSI finalizes Yessamin deal; NattoPharma gains U.S. patent for vitamin K2; DSM appoints Goppelsroeder nutritionals head; more news in brief.
Deals Shaping the Medical Industry (6/07)
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
Lilly's Chorus Experiment
With clinical failure rates rising industry-wide, a skunkworks at Lilly, called Chorus, has been trying to boost likely-to-succeed shots on goal by getting compounds to human proof-of-concept far faster and cheaper than the internal organization. Lilly's R&D group is skeptical about the program, even anxious -- one reason Chorus has teamed up with a major venture fund to get more molecules to test. If the program works, will Lilly embrace it - or will its venture partner reap the rewards?
Company Information
- Industry
- Diversified
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Devgen NV
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice